Should patients with impaired renal function, including those with end-stage renal disease or undergoing dialysis, receive the influenza (flu) vaccine annually?

Influenza Vaccination in Renal Disease

All patients with chronic kidney disease, including those with end-stage renal disease on dialysis, should receive annual inactivated influenza vaccination. 1, 2

Strength of Recommendation

The Canadian Society of Nephrology, endorsing KDIGO guidelines, provides a Grade 1B recommendation that all adults with CKD receive annual influenza vaccination unless contraindicated. 1 This recommendation applies across all stages of kidney disease, from early CKD through dialysis and transplantation. 2, 3

Rationale for Vaccination

• Patients with ESRD face substantially higher morbidity and mortality from influenza compared to the general population due to their immunocompromised state, frequent healthcare exposure, and multiple comorbidities. 4, 5
• Influenza can trigger clinical deterioration in dialysis patients, including cardiovascular events and increased hospitalization rates. 4
• The vaccine is publicly funded in Canada for high-risk populations including individuals with renal disease, facilitating access through primary care providers. 1

Vaccine Selection and Administration

• Use only inactivated influenza vaccine (IIV) or recombinant influenza vaccine (RIV) in patients with renal disease. 6, 7
• Live attenuated influenza vaccine (LAIV) is absolutely contraindicated in immunocompromised patients including those with ESRD. 6, 7, 8
• Standard age-appropriate dosing should be used—there is no recommendation for higher doses specifically for renal patients, unlike hepatitis B vaccination. 2, 8
• Administer annually before influenza season begins, ideally in early fall. 1, 5

Expected Immune Response

A critical caveat: immune response to influenza vaccine is significantly impaired in ESRD patients. 4, 9

• Seroconversion rates are lower than in healthy individuals, with variable immunogenicity depending on the degree of immunosuppression. 4, 9
• Despite reduced antibody response, vaccination still provides meaningful protection against severe disease outcomes in a significant proportion of patients. 4, 9
• One controversial study using natural experiment methodology found minimal vaccine effectiveness (0% for influenza-like illness, 2% for hospitalization, 0% for mortality) when comparing matched versus mismatched vaccine years. 10 However, this single study's methodology has limitations, and the consensus of guidelines remains strongly in favor of annual vaccination given the high risk of severe complications in unvaccinated patients. 1, 2, 11

Evidence Quality and Clinical Decision

The quality of evidence for influenza vaccine effectiveness in ESRD is admittedly very low, with only observational studies available and significant risk of bias. 11 However, given the extremely high rates of health-endangering events in dialysis patients, even modest vaccine effectiveness justifies annual vaccination. 11 The potential benefits clearly outweigh the minimal risks, and vaccination remains the best available preventive strategy. 4, 11

Safety Profile

• All available studies confirm excellent safety and tolerability of inactivated influenza vaccines in ESRD patients. 4, 9
• No serious adverse events have been documented in this population. 4
• The vaccine does not accelerate kidney disease progression or cause dialysis-related complications. 4

Additional Protective Measures

• Vaccinate close contacts and household members of dialysis patients to create a protective barrier. 8
• Healthcare workers in dialysis units should receive annual influenza vaccination to prevent nosocomial transmission. 8
• Implement strict infection control in dialysis units during influenza season, including masking symptomatic patients and maintaining physical separation. 7

Special Populations

For kidney transplant recipients: Annual inactivated influenza vaccination is recommended, ideally administered at least 3 months post-transplant when immunosuppression is less intense, though vaccination can be given as early as 1 month post-transplant during high influenza activity. 8 Live vaccines remain contraindicated. 8

For pediatric CKD patients: Follow standard pediatric immunization schedules with inactivated vaccines according to international recommendations. 1, 2

Common Pitfalls to Avoid

• Never use live attenuated influenza vaccine in any patient with renal disease or immunosuppression. 6, 7, 8
• Do not delay vaccination waiting for "optimal" timing—vaccinate as soon as vaccine becomes available each season. 5
• Do not assume vaccination provides complete protection—counsel patients that breakthrough infections can occur but are likely to be less severe. 4, 9
• Do not neglect vaccination of household contacts and caregivers, as this is a critical component of protecting vulnerable dialysis patients. 8